Cfi - complement component factor i Gene

Species: Mus musculus

Gene Type: protein coding
Gene ID: 12630

Summary

This gene encodes a serine protease that plays an important role in the classical and alternative complement pathways where it cleaves C4b and C3b components of C3 and C5 convertases. The encoded preproprotein undergoes proteolytic processing to generate an active, disulfide-linked heterodimeric enzyme comprised of heavy and light chains. [provided by RefSeq, Jul 2016]

Cfi Products (10)

mRNA Protein Name
NM_001329552.2 NP_001316481.1 complement factor I isoform 2 precursor
NM_001409673.1 NP_001396602.1 complement factor I isoform 3 preproprotein
NM_001409674.1 NP_001396603.1 complement factor I isoform 4 preproprotein
NM_001409679.1 NP_001396608.1 complement factor I isoform 5 preproprotein
NM_001409680.1 NP_001396609.1 complement factor I isoform 6 precursor
NM_001409681.1 NP_001396610.1 complement factor I isoform 7 preproprotein
NM_001409682.1 NP_001396611.1 complement factor I isoform 8 preproprotein
NM_001409683.1 NP_001396612.1 complement factor I isoform 9 preproprotein
NM_001409684.1 NP_001396613.1 complement factor I isoform 10 precursor
NM_007686.4 NP_031712.2 complement factor I isoform 1 preproprotein

Gene Ontology

  • Biological Process
Biological Process GO Annotation Evidence References Source
involved in complement activation IMP
IMP: Inferred from mutant phenotype
18202746 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

complement factor I

  • C3B/C4B inactivator

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Bioactive Molecules (4)
Cat. No. Product Name Effect
Purity Phase
HY-12300 Ocifisertib 99.78% Phase 2
HY-101340A Luvixasertib hydrochloride Inhibitor 99.63% Phase 2
HY-12300B Ocifisertib fumarate Inhibitor 98.69% Phase 2
HY-101340 Luvixasertib Inhibitor 99.9600% Phase 1

Pre-clinical Phase

Bioactive Molecules (9)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-132135 (1E)-CFI-400437 dihydrochloride Inhibitor 98.08% Unkown
HY-12300A Ocifisertib hydrochloride 98.29% Unkown
HY-116190 CFI-401870 Inhibitor / Unkown
HY-120032 CFI-401980 Inhibitor / Unkown
HY-120279A CFI-400437 Inhibitor / Unkown
HY-123675 CFI-400936 Inhibitor / Unkown
HY-RS02567 CFI Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS20677 Cfi Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS27188 Cfi Rat Pre-designed siRNA Set A Pre-designed Set / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Cfi NCBI NCBI:3426